In non-small cell lung cancer resistant to Osimertinib, Axl associates with EGFR and ErbB3, suggesting a prominent role of Axl and ErbB coexpression in the refractoriness to targeted therapy resistance (23). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.